Sab Biotherapeutics Stock Price Prediction
| SABS Stock | USD 3.96 0.12 2.94% |
Oversold Vs Overbought
45
Oversold | Overbought |
Quarterly Earnings Growth (0.60) | EPS Estimate Next Quarter (1.15) | EPS Estimate Current Year (3.64) | EPS Estimate Next Year (5.01) | Wall Street Target Price 12.4 |
Using SAB Biotherapeutics hype-based prediction, you can estimate the value of SAB Biotherapeutics from the perspective of SAB Biotherapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in SAB Biotherapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying SAB because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
SAB Biotherapeutics after-hype prediction price | USD 4.05 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
SAB |
SAB Biotherapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of SAB Biotherapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in SAB Biotherapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of SAB Biotherapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
SAB Biotherapeutics Estimiated After-Hype Price Volatility
In the context of predicting SAB Biotherapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on SAB Biotherapeutics' historical news coverage. SAB Biotherapeutics' after-hype downside and upside margins for the prediction period are 0.20 and 14.01, respectively. We have considered SAB Biotherapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
SAB Biotherapeutics is dangerous at this time. Analysis and calculation of next after-hype price of SAB Biotherapeutics is based on 3 months time horizon.
SAB Biotherapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as SAB Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading SAB Biotherapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with SAB Biotherapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.13 | 9.96 | 0.09 | 0.64 | 6 Events / Month | 3 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
3.96 | 4.05 | 2.27 |
|
SAB Biotherapeutics Hype Timeline
SAB Biotherapeutics is at this time traded for 3.96. The entity has historical hype elasticity of 0.09, and average elasticity to hype of competition of 0.64. SAB is forecasted to increase in value after the next headline, with the price projected to jump to 4.05 or above. The average volatility of media hype impact on the company the price is over 100%. The price appreciation on the next news is projected to be 2.27%, whereas the daily expected return is at this time at 1.13%. The volatility of related hype on SAB Biotherapeutics is about 1755.07%, with the expected price after the next announcement by competition of 4.60. SAB Biotherapeutics currently holds 5.91 M in liabilities with Debt to Equity (D/E) ratio of 0.16, which may suggest the company is not taking enough advantage from borrowing. Given the investment horizon of 90 days the next forecasted press release will be in about 6 days. Check out SAB Biotherapeutics Basic Forecasting Models to cross-verify your projections.SAB Biotherapeutics Related Hype Analysis
Having access to credible news sources related to SAB Biotherapeutics' direct competition is more important than ever and may enhance your ability to predict SAB Biotherapeutics' future price movements. Getting to know how SAB Biotherapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how SAB Biotherapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PBYI | Puma Biotechnology | 0.02 | 7 per month | 4.41 | 0.06 | 5.17 | (5.60) | 33.65 | |
| IOVA | Iovance Biotherapeutics | (0.45) | 9 per month | 0.00 | (0.1) | 7.18 | (7.12) | 22.30 | |
| SNDX | Syndax Pharmaceuticals | (0.46) | 9 per month | 0.00 | (0.09) | 4.02 | (5.34) | 34.00 | |
| PTGX | Protagonist Therapeutics | 3.16 | 7 per month | 0.00 | (0.09) | 3.42 | (3.82) | 16.19 |
SAB Biotherapeutics Additional Predictive Modules
Most predictive techniques to examine SAB price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for SAB using various technical indicators. When you analyze SAB charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About SAB Biotherapeutics Predictive Indicators
The successful prediction of SAB Biotherapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as SAB Biotherapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of SAB Biotherapeutics based on analysis of SAB Biotherapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to SAB Biotherapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to SAB Biotherapeutics's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 44.99 | 26.29 | 42.24 | 26.62 | Receivables Turnover | 7.6 | 4.3 | 3.87 | 3.16 |
Story Coverage note for SAB Biotherapeutics
The number of cover stories for SAB Biotherapeutics depends on current market conditions and SAB Biotherapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that SAB Biotherapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about SAB Biotherapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
SAB Biotherapeutics Short Properties
SAB Biotherapeutics' future price predictability will typically decrease when SAB Biotherapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of SAB Biotherapeutics often depends not only on the future outlook of the potential SAB Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. SAB Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.5 M | |
| Cash And Short Term Investments | 56.6 M |
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.